Keyword: Apotex

Eighteen months after Apotex's founder was murdered, his family has hired a financial adviser to weigh its options, Bloomberg reports.

FiercePharma’s most-read headlines of 2018 include industry themes that dominated the year's news or return time and again—and, of course, scandals.

Here is some news of note for the week: Apotex is dangling a $10 million reward in its CEO’s murder.

Former China FDA chief resigns over vaccine scandal; Astellas buys gene therapy specialist Quethera; FDA found problems at valsartan maker Huahai.

The FDA this month issued the Apotex Research Private plant in India a warning letter, its third in four years.

Apotex has secured the FDA's first approval as part of a new program designed to boost competition in certain drug classes.

Canada-based Apotex has agreed to merge its Australian business with that of India’s Strides Shasun.

Kroger and other grocery chains are suing Mylan, Teva, Endo and many other companies for an "overarching conspiracy" to artificially inflate prices.

Apotex CEO Jeremy Desai has resigned even as the company deals with the fallout from the murders of the company’s founder and his wife.

Legend teams with J&J on CAR-T project, Eisai and Biogen's Alzheimer's drug fails in early readout, Impax and Bora Pharma ink deal.